Treats overactive bladder with symptoms of urge urinary incontinence, urgency and…. ANDA 207681, held by Alembic. Darifenacin Hydrobromide.
As of Nov 16, 2026, ANDA 207681 (Darifenacin Hydrobromide), held by Alembic, was first approved by FDA on Dec 8, 2017, with 0 approved supplements and 0 published complete response letters.
Darifenacin is muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Dec 8, 2017 | Original application | Approved | None posted |
| Darifenacin HydrobromideEQ 7.5MG BASE · tablet, extended release;oral | Darifenacin Hydrobromide | Rx |
| Darifenacin HydrobromideEQ 15MG BASE · tablet, extended release;oral | Darifenacin Hydrobromide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters